Home Cart Sign in  
Chemical Structure| 68786-66-3 Chemical Structure| 68786-66-3

Structure of Triclabendazole
CAS No.: 68786-66-3

Chemical Structure| 68786-66-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Triclabendazole is a benzimidazole carbamate anthelmintic which can bind to beta-tublin and inhibits protein synthesis.

Synonyms: CGA89317; TCBZ; Egaten.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Triclabendazole

CAS No. :68786-66-3
Formula : C14H9Cl3N2OS
M.W : 359.66
SMILES Code : C2=C(OC1=C(Cl)C(=CC=C1)Cl)C(=CC3=C2N=C(SC)[NH]3)Cl
Synonyms :
CGA89317; TCBZ; Egaten.
MDL No. :MFCD03147039
InChI Key :NQPDXQQQCQDHHW-UHFFFAOYSA-N
Pubchem ID :50248

Safety of Triclabendazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Triclabendazole

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Adult Fasciola hepatica 15 μg/ml (33.2 µM) 12 hours (sensitive) or 24 hours (resistant) To evaluate the in vitro killing effect of triclabendazole on Fasciola hepatica and distinguish sensitive and resistant phenotypes by motility scoring Nat Commun. 2025 Mar 27;16(1):2996
MDA-MB-231 cells 160 µM 24 hours Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME, leading to cell swelling and large bubble formation, and enhances cell death via the ROS/JNK/Bax-mitochondrial apoptotic pathway. Front Pharmacol. 2021 Jul 8;12:670081
MCF-7 cells 160 µM 24 hours Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME, leading to cell swelling and large bubble formation, and enhances cell death via the ROS/JNK/Bax-mitochondrial apoptotic pathway. Front Pharmacol. 2021 Jul 8;12:670081
MDCK-II cells (transduced with human ABCG2) 15 µM 4 hours Evaluate the inhibitory effect of TCBZSO and TCBZSO2 on ABCG2-mediated transport of nitrofurantoin and danofloxacin, showing almost complete inhibition of human ABCG2 transport Antimicrob Agents Chemother. 2012 Jul;56(7):3535-43
THP-1 cells infected with Leishmania amazonensis amastigotes 0 to 500 µM 48 hours Evaluated the antiparasitic activity of triclabendazole against intracellular amastigotes, with an IC50 of 45.67 μM Front Cell Infect Microbiol. 2023 Jan 9;12:1044665
THP-1 cells 0 to 100 µM 48 or 72 hours Evaluated the cytotoxicity of triclabendazole on THP-1 cells, showing a CC50 of 39.4 μM at 72h treatment Front Cell Infect Microbiol. 2023 Jan 9;12:1044665
Leishmania amazonensis promastigotes 0 to 100 µM 72 hours Assessed the antiparasitic activity of triclabendazole against Leishmania amazonensis promastigotes, with an IC50 of 6 μM Front Cell Infect Microbiol. 2023 Jan 9;12:1044665
Juvenile Fasciola hepatica 30 µg/ml 72 hours To evaluate the in vitro fasciocidal activity of Triclabendazole and its metabolites against juvenile flukes. Results showed that Triclabendazole was more effective against juveniles than adults, while its metabolites had similar activity to controls. Antimicrob Agents Chemother. 2010 Nov;54(11):4596-604
Adult Fasciola hepatica 15 µg/ml 72 hours To evaluate the in vitro fasciocidal activity of Triclabendazole and its metabolites against adult flukes. Results showed that Triclabendazole had moderate activity, while its sulfoxide and sulfone metabolites caused death in 50% to 67% of flukes. Antimicrob Agents Chemother. 2010 Nov;54(11):4596-604

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Wistar rats Fasciola hepatica infection model Oral 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg Single dose, evaluated 1 week posttreatment To evaluate the in vivo efficacy of Triclabendazole monotherapy against adult and juvenile Fasciola hepatica infections. Results showed an ED50 of 2.7 mg/kg for adult flukes and weaker effects against juveniles. Antimicrob Agents Chemother. 2010 Nov;54(11):4596-604
BALB/c nude mice Breast cancer xenograft model Intraperitoneal injection 20 or 100 mg/kg Twice a week for 2 weeks Triclabendazole significantly reduced tumor volume by promoting the cleavage of caspase-3, PARP, and GSDME, inducing a switch from apoptosis to pyroptosis. Front Pharmacol. 2021 Jul 8;12:670081
Mice Abcg2−/− and wild-type mice Oral 50 mg/kg Single dose, sulfasalazine administered 15 minutes later Evaluate the effect of TCBZSO on Abcg2-mediated plasma levels of sulfasalazine, showing more than 1.5-fold increase in plasma concentration in wild-type mice Antimicrob Agents Chemother. 2012 Jul;56(7):3535-43

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01931085 Parasitic Disease NO_LONGER_AVAILABLE - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.78mL

0.56mL

0.28mL

13.90mL

2.78mL

1.39mL

27.80mL

5.56mL

2.78mL

References

 

Historical Records

Categories